Advanced Cell Tech (ACTC) 6.9700 $ACTC
Bankruptcies, Breakouts, and Busts; What's Happening in Biotech?
ACCESSWIRE - Tue Nov 11, 10:34AM CST
CORAL GABLES, FL / ACCESSWIRE / November 11, 2014 / From prostate cancer drugs to stem-cell therapy, the biotech industry seems to encompass a variety of unique and innovative companies. According to market research firm IBISWorld, the global revenue of the Biotech industry is nearly $300 billion. Statista reports that more that $50Billion of US biopharmaceutical goods are exported and the industry is on pace to grow at a compounded annual rate of nearly 11%. IBIS notes that many small companies, alongside a few industry giants in pharmaceutical, chemical and agricultural firms, populate the global biotech industry. There is also a lower level of market share concentration as noted by IBISWorld estimates that the top four industry players will account for less than 28% of the industry's revenue in 2014. With so much potential there are certainly companies in the market, which have progressed to the next level and others that have mismanaged their businesses into bankruptcy.
DNDN: 0.13 (-0.02)
Advanced Cell Technology: All Systems Go
Biotech Research Group - at Seeking Alpha - Tue Nov 11, 10:14AM CST
StemCells Inc. Faces Tough Times Ahead
Tom Franey - Seeking Alpha - Mon Nov 10, 9:36AM CST
StemCells Inc. (NASDAQ: STEM ) is a small cap biotech company primarily involved in stem cell research. Its stock is currently trading at $1.16, which is 50% of its recent highs. Disappointing Results In June of this year, STEM issued a press...
STEM: 0.90 (+0.03)
Advanced Cell Technology Is Severely Undervalued
Tom Franey - at Seeking Alpha - Fri Nov 07, 4:32PM CST
Advanced Cell reports November 10
Seeking Alpha - at Seeking Alpha - Fri Nov 07, 8:39AM CST
Advanced Cell Technology to Host Conference Call and Webcast to Provide a Corporate Update for the Third Quarter of 2014
Business Wire - Fri Nov 07, 8:09AM CST
Advanced Cell Technology, Inc. ("ACT"; OTCBB: ACTC), a leader in the field of regenerative medicine, announced today that the company will host a conference call on Monday, November 10, 2014 at 4:30 p.m. EST during which it will provide a corporate update for the third quarter of 2014.
Time To Sell Advanced Cell Technology And Buy StemCells, Inc.
JMY Investments - at Seeking Alpha - Mon Nov 03, 9:09AM CST
STEM: 0.90 (+0.03)
Advanced Cell Technology Is Scaling Up Its Blood Program
BiOCell - at Seeking Alpha - Mon Oct 27, 7:35AM CDT
Advanced Cell Technology Appoints LeRoux Jooste as SVP of Business Development & Chief Commercial Officer
Business Wire - Mon Oct 20, 8:02AM CDT
Advanced Cell Technology, Inc. ("ACT"; OTCBB: ACTC), a leader in the field of regenerative medicine, today announced the appointment of LeRoux Jooste to the newly created position of Senior Vice President of Business Development and Chief Commercial Officer. LeRoux has a global track record of building commercial capability and proven success in launching blockbuster products in the USA and Europe. LeRoux joins ACT from Antares Pharma Inc. (NASDAQ: ATRS), where he served as Senior Vice President and General Manager, Pharmaceuticals since May 2012.
ATRS: 2.65 (+0.03)
ACT Reports the Publication of Research on the Scalable Generation of Universal Platelets from Human Induced Pluripotent Stem Cells (iPSC)
Business Wire - Fri Oct 17, 8:09AM CDT
Advanced Cell Technology, Inc. ("ACT"; OTCBB: ACTC), a leader in the field of regenerative medicine, reported today that its proprietary iPSC Platelet technology is potentially capable of producing large-scale quantities of universal donor platelets for transfusion in almost any patient.
Advanced Cell Technology Has Groundbreaking Results
BiOCell - at Seeking Alpha - Wed Oct 15, 3:06PM CDT
Update: Advanced Cell Technology Interim Results And Shelf Offerings
Esekla - at Seeking Alpha - Wed Oct 15, 8:37AM CDT
RPE cells safety data published online in The Lancet
Seeking Alpha - at Seeking Alpha - Wed Oct 15, 6:50AM CDT
STEM: 0.90 (+0.03)
Market Maker Surveillance Report. DORLO, CNET, ACTC, XCO, STRP, NETE, Winning Stocks With Lowest Price Friction For Tuesday, October 14th 2014
M2 - Wed Oct 15, 3:27AM CDT
BUYINS.NET / www.buyins.net, announced today its proprietary Market Maker Friction Factor Report for Tuesday. Since October 2008 market makers are now required to be on the bid as much as they are on the offer and for like amounts of stock. This Fair Market Making Requirement is designed to prevent market makers from manipulating stock prices. On Tuesday there were 4904 companies with "abnormal" market making, 2632 companies with positive Friction Factors and 2319 companies with negative Friction Factors. Here is a list of the top companies with the largest percentage gain per share Tuesday and low price friction (bullish). This means that there was more buying than selling in the stocks and their stock prices rose faster with less Friction. Doral Financial Corp (OTC
ORLO), Chinanet Online Holdings Inc (NASDAQ:CNET), Advanced Cell Technology Inc (OTC:ACTC), EXCO Resources Inc (NYSE:XCO), Strata Capital Corp. (NYSE:STRP), NET ELEMENT INC (OTC:NETE). To access Friction Factor, Naked Short Data and SqueezeTrigger Prices on all stocks please visit http://www.buyins.net .
NETE: 1.20 (unch), XCO: 2.38 (-0.03), DRL: 3.38 (-0.02), STRP: 19.49 (-0.09), CNET: 1.28 (-0.11)
ACT Announces Positive Results from Two Clinical Trials Published in The Lancet Using Differentiated Stem Cell-Derived Retinal Pigment Epithelium (RPE) Cells for the Treatment of Macular Degeneration
Business Wire - Tue Oct 14, 5:33PM CDT
--ACT to Host a Conference Call on Wednesday, October 15, 2014 at 4:30 PM Eastern Time. Interested Parties may access the call live by dialing (888) 264-3177 and using Conference ID 18428590. A Webcast is available at http://engage.vevent.com/rt/act~advancedcelltechnology101514
Advanced Cell Technology approves one:100 reverse stock split
M2 - Thu Aug 28, 5:23AM CDT
Regenerative medicine company Advanced Cell Technology (OTCBB:ACTC) revealed on Wednesday the completion of a 1:100 reverse split of its common stock.
Advanced Cell Technology Announces 1:100 Reverse Stock Split
Business Wire - Wed Aug 27, 4:12PM CDT
Advanced Cell Technology, Inc. ("ACT"; OTCBB: ACTC), a leader in the field of regenerative medicine, today announced that it has completed a 1:100 reverse split of its common stock.
Global Regenerative Medicines Market (Technology, Application and Geography) - Forecast to 2020
M2 - Mon Aug 18, 8:49AM CDT
Research and Markets (http://www.researchandmarkets.com/research/47gb9g/global) has announced the addition of the "Global Regenerative Medicines Market (Technology, Application and Geography) - Size, Global Trends, Company Profiles, Demand, Insights, Analysis, Research, Report, Opportunities, Segmentation and Forecast, 2013 - 2020" report to their offering. According to a new market research repor titled, "GlobalRegenerative MedicineMarket (Technology, Applications, Geography) - Industry Analysis, Trends, Opportunities and Forecast, 2013-2020", the global regenerative medicine market will reach $ 67.6 billion by 2020 from $16.4 billion in 2013, registering a CAGR of 23.2% during forecast period (2014 - 2020). Small molecules and biologics segment holds prominent market share in the overall regenerative medicine technology market and is anticipated to grow at a CAGR of 18.9% during the forecast period. Regenerative medicines have the ability to restore the lost functionality of tissues or organs, unlike conventional medicines, which are palliative. The immense potential of these medicines in repairing or regenerating diseased organs is the major reason for intensive focus on research and development in this field. The technologies implemented for these medicines utilize various cell types including stem cells. The advancements in nanotechnology and stem cells application would account for further progress of this novel field of medicine. The global regenerative medicine market is segmented based on technologies into small molecules and biologics, gene therapy and cell therapy. Key Topics Covered: CHAPTER 1. INTRODUCTION CHAPTER 2. EXECUTIVE SUMMARY CHAPTER 3. GLOBAL REGENERATIVE MEDICINES MARKET OVERVIEW CHAPTER 4. GLOBAL REGENERATIVE MEDICINE MARKET BY TECHNOLOGIES CHAPTER 5. GLOBAL REGENERATIVE MEDICINE MARKET BY APPLICATIONS CHAPTER 6. GLOBAL REGENERATIVE MEDICINES MARKET BY GEOGRAPHY CHAPTER 7. COMPANY PROFILES Companies Mentioned: - Advanced Cell Technology - Athersys Inc. - Cytomedix - Cytori Therapeutics - Genzyme - Kinetic Concepts - Mesoblast Ltd. - NuVasive - Shire pharmaceuticals - Stem Cells For more information visit http://www.researchandmarkets.com/research/47gb9g/global
CYTX: 0.48 (-0.01), ATHX: 1.30 (-0.03)
Advanced Cell Technology to Host Conference Call to Provide a Corporate Update
Business Wire - Wed Aug 06, 3:31PM CDT
Advanced Cell Technology, Inc. ("ACT"; OTCBB:ACTC), a leader in the field of regenerative medicine, announced today will host a conference call on Monday, August 11, 2014 at 5:00 p.m. EDT during which it will provide a corporate update.
Advanced Cell Technology Secures $30 Million Equity Facility from Lincoln Park Capital
Business Wire - Thu Jul 03, 8:05AM CDT
Advanced Cell Technology, Inc. ("ACT"
(OTCBB:ACTC), a leader in the field of regenerative medicine, today announced that it has entered into a $30 million common stock purchase agreement with Lincoln Park Capital Fund, LLC ("LPC" .
Bankruptcies, Breakouts, and Busts; What's Happening in Biotech?
ACCESSWIRE - Tue Nov 11, 10:34AM CST
CORAL GABLES, FL / ACCESSWIRE / November 11, 2014 / From prostate cancer drugs to stem-cell therapy, the biotech industry seems to encompass a variety of unique and innovative companies. According to market research firm IBISWorld, the global revenue of the Biotech industry is nearly $300 billion. Statista reports that more that $50Billion of US biopharmaceutical goods are exported and the industry is on pace to grow at a compounded annual rate of nearly 11%. IBIS notes that many small companies, alongside a few industry giants in pharmaceutical, chemical and agricultural firms, populate the global biotech industry. There is also a lower level of market share concentration as noted by IBISWorld estimates that the top four industry players will account for less than 28% of the industry's revenue in 2014. With so much potential there are certainly companies in the market, which have progressed to the next level and others that have mismanaged their businesses into bankruptcy.
DNDN: 0.13 (-0.02)
Advanced Cell Technology: All Systems Go
Biotech Research Group - at Seeking Alpha - Tue Nov 11, 10:14AM CST
StemCells Inc. Faces Tough Times Ahead
Tom Franey - Seeking Alpha - Mon Nov 10, 9:36AM CST
StemCells Inc. (NASDAQ: STEM ) is a small cap biotech company primarily involved in stem cell research. Its stock is currently trading at $1.16, which is 50% of its recent highs. Disappointing Results In June of this year, STEM issued a press...
STEM: 0.90 (+0.03)
Advanced Cell Technology Is Severely Undervalued
Tom Franey - at Seeking Alpha - Fri Nov 07, 4:32PM CST
Advanced Cell reports November 10
Seeking Alpha - at Seeking Alpha - Fri Nov 07, 8:39AM CST
Advanced Cell Technology to Host Conference Call and Webcast to Provide a Corporate Update for the Third Quarter of 2014
Business Wire - Fri Nov 07, 8:09AM CST
Advanced Cell Technology, Inc. ("ACT"; OTCBB: ACTC), a leader in the field of regenerative medicine, announced today that the company will host a conference call on Monday, November 10, 2014 at 4:30 p.m. EST during which it will provide a corporate update for the third quarter of 2014.
Time To Sell Advanced Cell Technology And Buy StemCells, Inc.
JMY Investments - at Seeking Alpha - Mon Nov 03, 9:09AM CST
STEM: 0.90 (+0.03)
Advanced Cell Technology Is Scaling Up Its Blood Program
BiOCell - at Seeking Alpha - Mon Oct 27, 7:35AM CDT
Advanced Cell Technology Appoints LeRoux Jooste as SVP of Business Development & Chief Commercial Officer
Business Wire - Mon Oct 20, 8:02AM CDT
Advanced Cell Technology, Inc. ("ACT"; OTCBB: ACTC), a leader in the field of regenerative medicine, today announced the appointment of LeRoux Jooste to the newly created position of Senior Vice President of Business Development and Chief Commercial Officer. LeRoux has a global track record of building commercial capability and proven success in launching blockbuster products in the USA and Europe. LeRoux joins ACT from Antares Pharma Inc. (NASDAQ: ATRS), where he served as Senior Vice President and General Manager, Pharmaceuticals since May 2012.
ATRS: 2.65 (+0.03)
ACT Reports the Publication of Research on the Scalable Generation of Universal Platelets from Human Induced Pluripotent Stem Cells (iPSC)
Business Wire - Fri Oct 17, 8:09AM CDT
Advanced Cell Technology, Inc. ("ACT"; OTCBB: ACTC), a leader in the field of regenerative medicine, reported today that its proprietary iPSC Platelet technology is potentially capable of producing large-scale quantities of universal donor platelets for transfusion in almost any patient.
Advanced Cell Technology Has Groundbreaking Results
BiOCell - at Seeking Alpha - Wed Oct 15, 3:06PM CDT
Update: Advanced Cell Technology Interim Results And Shelf Offerings
Esekla - at Seeking Alpha - Wed Oct 15, 8:37AM CDT
RPE cells safety data published online in The Lancet
Seeking Alpha - at Seeking Alpha - Wed Oct 15, 6:50AM CDT
STEM: 0.90 (+0.03)
Market Maker Surveillance Report. DORLO, CNET, ACTC, XCO, STRP, NETE, Winning Stocks With Lowest Price Friction For Tuesday, October 14th 2014
M2 - Wed Oct 15, 3:27AM CDT
BUYINS.NET / www.buyins.net, announced today its proprietary Market Maker Friction Factor Report for Tuesday. Since October 2008 market makers are now required to be on the bid as much as they are on the offer and for like amounts of stock. This Fair Market Making Requirement is designed to prevent market makers from manipulating stock prices. On Tuesday there were 4904 companies with "abnormal" market making, 2632 companies with positive Friction Factors and 2319 companies with negative Friction Factors. Here is a list of the top companies with the largest percentage gain per share Tuesday and low price friction (bullish). This means that there was more buying than selling in the stocks and their stock prices rose faster with less Friction. Doral Financial Corp (OTC
ORLO), Chinanet Online Holdings Inc (NASDAQ:CNET), Advanced Cell Technology Inc (OTC:ACTC), EXCO Resources Inc (NYSE:XCO), Strata Capital Corp. (NYSE:STRP), NET ELEMENT INC (OTC:NETE). To access Friction Factor, Naked Short Data and SqueezeTrigger Prices on all stocks please visit http://www.buyins.net . NETE: 1.20 (unch), XCO: 2.38 (-0.03), DRL: 3.38 (-0.02), STRP: 19.49 (-0.09), CNET: 1.28 (-0.11)
ACT Announces Positive Results from Two Clinical Trials Published in The Lancet Using Differentiated Stem Cell-Derived Retinal Pigment Epithelium (RPE) Cells for the Treatment of Macular Degeneration
Business Wire - Tue Oct 14, 5:33PM CDT
--ACT to Host a Conference Call on Wednesday, October 15, 2014 at 4:30 PM Eastern Time. Interested Parties may access the call live by dialing (888) 264-3177 and using Conference ID 18428590. A Webcast is available at http://engage.vevent.com/rt/act~advancedcelltechnology101514
Advanced Cell Technology approves one:100 reverse stock split
M2 - Thu Aug 28, 5:23AM CDT
Regenerative medicine company Advanced Cell Technology (OTCBB:ACTC) revealed on Wednesday the completion of a 1:100 reverse split of its common stock.
Advanced Cell Technology Announces 1:100 Reverse Stock Split
Business Wire - Wed Aug 27, 4:12PM CDT
Advanced Cell Technology, Inc. ("ACT"; OTCBB: ACTC), a leader in the field of regenerative medicine, today announced that it has completed a 1:100 reverse split of its common stock.
Global Regenerative Medicines Market (Technology, Application and Geography) - Forecast to 2020
M2 - Mon Aug 18, 8:49AM CDT
Research and Markets (http://www.researchandmarkets.com/research/47gb9g/global) has announced the addition of the "Global Regenerative Medicines Market (Technology, Application and Geography) - Size, Global Trends, Company Profiles, Demand, Insights, Analysis, Research, Report, Opportunities, Segmentation and Forecast, 2013 - 2020" report to their offering. According to a new market research repor titled, "GlobalRegenerative MedicineMarket (Technology, Applications, Geography) - Industry Analysis, Trends, Opportunities and Forecast, 2013-2020", the global regenerative medicine market will reach $ 67.6 billion by 2020 from $16.4 billion in 2013, registering a CAGR of 23.2% during forecast period (2014 - 2020). Small molecules and biologics segment holds prominent market share in the overall regenerative medicine technology market and is anticipated to grow at a CAGR of 18.9% during the forecast period. Regenerative medicines have the ability to restore the lost functionality of tissues or organs, unlike conventional medicines, which are palliative. The immense potential of these medicines in repairing or regenerating diseased organs is the major reason for intensive focus on research and development in this field. The technologies implemented for these medicines utilize various cell types including stem cells. The advancements in nanotechnology and stem cells application would account for further progress of this novel field of medicine. The global regenerative medicine market is segmented based on technologies into small molecules and biologics, gene therapy and cell therapy. Key Topics Covered: CHAPTER 1. INTRODUCTION CHAPTER 2. EXECUTIVE SUMMARY CHAPTER 3. GLOBAL REGENERATIVE MEDICINES MARKET OVERVIEW CHAPTER 4. GLOBAL REGENERATIVE MEDICINE MARKET BY TECHNOLOGIES CHAPTER 5. GLOBAL REGENERATIVE MEDICINE MARKET BY APPLICATIONS CHAPTER 6. GLOBAL REGENERATIVE MEDICINES MARKET BY GEOGRAPHY CHAPTER 7. COMPANY PROFILES Companies Mentioned: - Advanced Cell Technology - Athersys Inc. - Cytomedix - Cytori Therapeutics - Genzyme - Kinetic Concepts - Mesoblast Ltd. - NuVasive - Shire pharmaceuticals - Stem Cells For more information visit http://www.researchandmarkets.com/research/47gb9g/global
CYTX: 0.48 (-0.01), ATHX: 1.30 (-0.03)
Advanced Cell Technology to Host Conference Call to Provide a Corporate Update
Business Wire - Wed Aug 06, 3:31PM CDT
Advanced Cell Technology, Inc. ("ACT"; OTCBB:ACTC), a leader in the field of regenerative medicine, announced today will host a conference call on Monday, August 11, 2014 at 5:00 p.m. EDT during which it will provide a corporate update.
Advanced Cell Technology Secures $30 Million Equity Facility from Lincoln Park Capital
Business Wire - Thu Jul 03, 8:05AM CDT
Advanced Cell Technology, Inc. ("ACT"
(OTCBB:ACTC), a leader in the field of regenerative medicine, today announced that it has entered into a $30 million common stock purchase agreement with Lincoln Park Capital Fund, LLC ("LPC" . 
